Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) has a beta value of 2.09 and has seen 6.75 million shares traded in the last trading session. The company, currently valued at $20.26M, closed the last trade at $0.15 per share which meant it gained $0.01 on the day or 5.13% during that session. The TNXP stock price is -14660.0% off its 52-week high price of $22.14 and 20.0% above the 52-week low of $0.12. If we look at the company’s 10-day average daily trading volume, we find that it stood at 18.63 million shares traded. The 3-month trading volume is 26.36 million shares.
The consensus among analysts is that Tonix Pharmaceuticals Holding Corp (TNXP) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -2.93.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) trade information
Sporting 5.13% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the TNXP stock price touched $0.15 or saw a rise of 16.39%. Year-to-date, Tonix Pharmaceuticals Holding Corp shares have moved -98.86%, while the 5-day performance has seen it change 5.88%. Over the past 30 days, the shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) have changed -7.58%. Short interest in the company has seen 8.29 million shares shorted with days to cover at 0.24.
Tonix Pharmaceuticals Holding Corp (TNXP) estimates and forecasts
Figures show that Tonix Pharmaceuticals Holding Corp shares have outperformed across the wider relevant industry. The company’s shares have lost -97.16% over the past 6 months, with this year growth rate of 91.78%, compared to 19.10% for the industry. Revenue growth from the last financial year stood is estimated to be 59.40%.
3 analysts offering their estimates for the company have set an average revenue estimate of 3.08M for the current quarter. 3 have an estimated revenue figure of 3.4M for the next ending quarter. Year-ago sales stood 3.99M and 3.78M respectively for this quarter and the next, and analysts expect sales will shrink by -22.80% for the current quarter and 59.40% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 79.31% over the past 5 years.
TNXP Dividends
Tonix Pharmaceuticals Holding Corp is expected to release its next earnings report in November this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s Major holders
Insiders own 0.21% of the company shares, while shares held by institutions stand at 0.29% with a share float percentage of 0.29%. Investors are also buoyed by the number of investors in a company, with Tonix Pharmaceuticals Holding Corp having a total of 32.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . As of Jun 30, 2024 , the former fund manager holds about 0.01% shares in the company for having 18.09 shares of worth $2670.0 while later fund manager owns 7.3 shares of worth $1077.0 as of Jun 30, 2024 , which makes it owner of about 0.01% of company’s outstanding stock.
